For research and educational purposes only. Not medical advice.
Eszopiclone Reference
Educational, not medical advice reference for Eszopiclone: Sleep; regulatory status, evidence posture, source review, and schedule notes. Also known as Lunes…
Reference summary
Krystal 2003 Sleep demonstrated sustained efficacy over 6 months of nightly treatment in adults with chronic insomnia - one of the longer-duration sustained-efficacy datasets for any hypnotic. The 2014 FDA dose-reduction recommendation lowered the starting dose from 2 mg to 1 mg based on next-morning driving impairment data.
Regulatory and posture
- Categories
- Sleep
- Aliases
- Lunesta, S-enantiomer of zopiclone, Non-benzodiazepine GABA-A agonist (small molecule, not a peptide)
- Evidence posture
- human - 2014 FDA dose reduction (2 mg -> 1 mg starting dose) due to next-morning driving impairment. Same class-level safety concerns as zolpidem.
- Regulatory status
- FDA-approved as Lunesta (2004) for the treatment of insomnia. Schedule IV controlled substance. The recommended starting dose was reduced in 2014 (FDA safety announcement on next-morning impairment).
- Content review status
- label verified